Filing identity and reporting period
The supplied filing text is for MEI Pharma, Inc. (Nasdaq: MEIP), a quarterly report for the three and nine months ended March 31, 2016, signed May 4, 2016. This conflicts with the request metadata identifying Lite Strategy, Inc. and 2014 Q3; the summary below reflects the filing text, not that metadata.
Business context and results
MEI Pharma is a clinical-stage oncology company developing Pracinostat, ME-401 and ME-344. It reported no revenue; operations and cash use principally reflect drug development and corporate expenses. Interim results are unaudited.
| Metric | Three months ended Mar. 31, 2016 | Three months ended Mar. 31, 2015 | Nine months ended Mar. 31, 2016 | Nine months ended Mar. 31, 2015 |
|---|---|---|---|---|
| Research and development expense | $3.420 million | $6.775 million | $9.418 million | $20.044 million |
| General and administrative expense | $1.990 million | $2.185 million | $5.765 million | $7.039 million |
| Total operating expenses / operating loss | $5.410 million | $8.960 million | $15.183 million | $27.083 million |
| Net loss | $5.371 million | $8.930 million | $15.092 million | $27.032 million |
| Net loss per share, basic and diluted | $0.16 | $0.27 | $0.44 | $1.03 |
All dollar amounts in the table are expenses or losses, in U.S. dollars. Interest and dividend income was $39,000 for the quarter and $92,000 for the nine-month period in 2016, compared with $30,000 and $52,000, respectively, in 2015. No operating margin is meaningful because the company had no reported revenue.
Financial position, liquidity and cash flow
- At March 31, 2016, cash, cash equivalents and short-term investments totaled $49.402 million, down from $63.779 million at June 30, 2015. This included $35.111 million of short-term U.S. government securities.
- Total current assets were $50.504 million and current liabilities $4.025 million, for working capital of approximately $46.479 million. Total assets were $50.931 million; stockholders’ equity was $46.906 million.
- The balance sheet reports no debt. The filing identifies current liabilities, commitments and contingencies but no borrowings.
- For the nine months ended March 31, 2016, net cash used in operating activities was $14.374 million; investing activities provided $9.943 million, primarily from investment maturities exceeding purchases; financing activities provided no cash. Cash and cash equivalents declined by $4.431 million to $14.291 million.
- Management said existing cash, cash equivalents and short-term investments were expected to fund operations through at least fiscal 2017. The company expected to seek future capital transactions or strategic partnerships to continue development.
Changes versus comparable periods
Quarterly net loss narrowed to $5.371 million from $8.930 million; nine-month net loss narrowed to $15.092 million from $27.032 million. Management attributed lower R&D costs mainly to reduced spending on Pracinostat MDS trials and manufacturing, and lower nine-month ME-344 trial costs. G&A declined primarily because of lower share-based compensation. Cash used in operations also fell, from $21.327 million to $14.374 million for the nine-month periods. Unlike the prior-year comparable period, which included $43.070 million of net proceeds from an equity offering, the current period had no financing proceeds.
Outlook, developments and risks
- Management expected to begin a Phase III registration-oriented Pracinostat-plus-azacitidine study in elderly patients with newly diagnosed AML in the second half of calendar 2016. The prior Phase II Pracinostat MDS study failed its primary endpoint; exploratory analyses in patients tolerating at least four cycles were described as favorable.
- The FDA had approved the ME-401 Investigational New Drug application in March 2016. The company expected a Phase Ib study in recurrent CLL or follicular non-Hodgkin lymphoma in Q2 2016.
- An investigator-sponsored ME-344 study with bevacizumab in HER2-negative breast cancer was expected to start in Q2 2016. ME-344 combined with topotecan had shown insufficient activity to warrant further development.
- Management expected continued operating losses and negative operating cash flows. Risks include the need for additional financing, clinical trial failure or delay, regulatory uncertainty, commercialization and market-acceptance challenges, competition, manufacturing costs, and intellectual-property exposure.
- Potential Pracinostat milestone payments to S*Bio could total up to $75.2 million upon specified regulatory and sales milestones; $250,000 was accrued at March 31, 2016. The first pivotal-trial dosing milestone includes $200,000 cash plus $500,000 in common stock. The office lease was extended in April 2016 through June 30, 2017.
- The company reported no legal proceedings and no material change in risk factors from its prior annual report. Management stated disclosure controls were effective and there were no material changes to internal control over financial reporting.
Most important facts for investors to verify
- Confirm the filing identity and period: the source is MEI Pharma’s March 31, 2016 Form 10-Q, not a Lite Strategy, Inc. 2014 Q3 filing.
- Assess whether the $49.4 million liquidity balance and management’s runway estimate through at least fiscal 2017 remain adequate against clinical-development plans and expected cash burn.
- Track execution and results of the planned Pracinostat, ME-401 and ME-344 studies, including whether expected start dates were met and whether clinical evidence supports further development.
- Review the potential timing and amount of S*Bio milestone obligations and the company’s ability to raise capital; shelf-registration sales were restricted by the public-float limitation described in the filing.